Novo Nordisk faces slowing semaglutide momentum as new obesity contenders, including GPCR's aleniglipron, push the ...
Zacks Investment Research on MSN
NVO down 42% year to date: Is this an indication to sell the stock?
Novo Nordisk NVO has stumbled through 2025, with its shares down 41.5% year to date despite finally resolving U.S. supply constraints for its semaglutide-based GLP-1 blockbusters — Ozempic for type II ...
Even so, in an interview with The Economist, Mr Doustdar sounded confident that Novo can recover. His prescription is to push ...
Democratic senators are demanding more details on the drug pricing deals that Pfizer Inc., Eli Lilly & Co. and others have ...
Pharmaceutical Technology on MSN
Moderna signs deal worth up to $503m with Nanexa
Moderna is seeking to enhance some of its drugs with Nanexa’s technology as the biologics sector moves to less frequent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback